Sanofi (ETR:SNW)
80.62
+1.40 (1.77%)
Feb 2, 2026, 5:27 PM CET
Sanofi Revenue
In the year 2025, Sanofi had annual revenue of 46.72B EUR with 5.49% growth. Sanofi had revenue of 12.21B in the quarter ending December 31, 2025, with 6.87% growth.
Revenue
46.72B
Revenue Growth
+5.49%
P/S Ratio
2.05
Revenue / Employee
563.67K
Employees
82,878
Market Cap
95.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Sanofi News
- 3 days ago - Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval - GuruFocus
- 3 days ago - Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News - The Motley Fool
- 3 days ago - Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation - Seeking Alpha
- 3 days ago - Sanofi Announces Positive CHMP Opinion For Rezurock In EU - Finanz Nachrichten
- 3 days ago - Sanofi (SNY) Gains EU Panel Support for Rezurock Approval - GuruFocus
- 3 days ago - Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds - Seeking Alpha
- 3 days ago - Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease - GlobeNewsWire
- 3 days ago - Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... - GuruFocus